EU Patent Granted to Dark Canyon Labs

Dark Canyon Labs was notified of intention to grant European Union Patent No. EP2421373 for development of a novel Colon Lavage System on April 15, 2019.

Dark Canyon Labs is especially pleased to announce that this EU Patent for DCL-101, a novel taste-free pill prep, used for colonoscopy preparation, joins patents for DCL-101 already issued in the US, Japan, Australia, Canada, and China. Patent is pending in Hong Kong.

March is Colorectal Cancer Awareness Month

Colorectal cancer is the third leading cause of cancer-related deaths in men and women in the United States, and kills over 50,000 people annually. Colorectal cancer can be prevented by getting screened.

Historically, one of the obstacles of getting a screening colonoscopy has been the bad taste and tolerability of the colonoscopy prep, which must be taken prior to the procedure. Dark Canyon Labs has developed a new colonoscopy prep, DCL-101, which is a taste-free pill prep. A Phase 2 clinical trial was successfully completed, with Phase 3 to begin in the near future.

Dark Canyon Labs is determined to make a safe and effective taste-free pill prep available for patients. Our goal is to make the process of prepping for a colonoscopy much easier and to increase colonoscopy screening rates, thereby saving lives. Get screened and prevent colorectal cancer!

For more information, visit the American Society for Gastrointestinal Endoscopy.

Phase 2 Results of Dark Canyon Labs' Novel Pill Prep DCL-101 Selected as one of the "Most Innovative and Impactful Abstracts at ACG 2018"

The American College of Gastroenterology’s (ACG) Innovation & Technology Committee recently selected 22 abstracts as the “Most Innovative and Impactful Abstracts at ACG 2018”, from over 2600 abstracts that were presented at the ACG’s annual Scientific Meeting in Philadelphia, PA in October 2018.

Dark Canyon Labs’ presentation of Phase 2 study results of the Novel Pill Prep, DCL-101, was selected as one of the “Most Innovative and Impactful Abstracts at ACG 2018.”

The ACG Innovation & Technology Committee is a forum that allows members to gather information about new ideas, innovations and technologies in gastroenterology. Selecting the “Most Innovative and Impactful Abstracts at ACG 2018” allowed the Committee to highlight the clinical significance and importance of emerging technologies in gastroenterology.

See the complete ACG report here.

Dark Canyon Labs announces completion of Phase 2 Clinical Trial

Dark Canyon Labs is pleased to announce the completion of a multicenter, randomized, investigator blinded, non-inferiority Phase 2 Clinical Trial.  DCL-101, a novel Pill Prep, was compared to standard split-dose GoLYTELY® in adult outpatients undergoing routine colonoscopy.

Based on tolerability, safety, and efficacy results, Dark Canyon Labs is excited to announce that DCL-101 will move ahead for further evaluation in two definitive Phase 3 trials.  

Watch for additional details soon. For more information, contact  

Dark Canyon Labs announces start of Phase 2 Clinical Trial in December 2016

Dark Canyon Labs is pleased to announce that subject enrollment begins in December for a Phase 2 trial comparing the safety and efficacy of DCL-101 vs. GoLYTELY® in preparing the bowel for routine colonoscopy.  DCL-101 is Dark Canyon Labs' novel capsule prep that eliminates the need to drink the salty-tasting solution of other preps, completely transforming the patient experience. GoLYTELY® is the current gold standard bowel prep in terms of efficacy, so will be used as the comparator.  

The trial is now listed on, a service of the National Institutes of Health.

To learn more about enrolling in the clinical trial, please contact Philip Calvillo from Robarts Clinical Trials, at 626-658-0870 or 



Dark Canyon Laboratories to present at 2016 AGA Tech Summit

Dr. Bachwich will be presenting details about Dark Canyon Labs' new colonoscopy prep, DCL-101,  at the "Shark Tank" Session of the 2016 AGA Tech Summit in Boston, MA on Thursday, March 31, 2016. This conference on GI Innovation and Technology identifies unmet needs in gastroenterology and highlights promising new technologies.  A distinguished panel of moderators will provide valuable feedback.  


Dark Canyon Labs supports Colorectal Cancer Awareness Month in March

Colon cancer kills 50,000 patients every year and is the third leading cause of cancer in men and women in the U.S.  Many of these deaths can be prevented with regular screening.  Dark Canyon Laboratories is committed to providing patients with a much better experience during the colonoscopy prep process.  A better tolerated prep could help save lives by increasing the colon cancer screening rate. If patients don't dread the process, they will be more likely to comply with the current screening recommendations.

Learn more about colorectal cancer from the American College of Gastroenterology and from the American Cancer Society.

Dark Canyon Laboratories Plans Phase 2 Clinical Trial

Robarts Clinical Trials, Inc. has been retained by Dark Canyon Labs to conduct a Phase 2 Clinical Trial beginning late 2016.  The trial will enroll approximately 357 patients across 7 investigative sites. This randomized, investigator-blinded, non-inferiority study will compare the safety and efficacy of DCL-101 to the current gold standard of colonoscopy preps, GoLYTELY®.  Additional data on tolerability and patient preferences will be collected.  

A subsidiary of the University of Western Ontario, Robarts is a global academic Clinical Research Organization (CRO) that provides a broad range of clinical research services to pharmaceutical and biotechnology companies, government agencies and academic investigators.

Dark Canyon Labs is especially excited to be working with Robarts because they are globally recognized for their innovation and specialized expertise in the processing and centralized review of GI endoscopic video recordings with Central Image Management Solutions (CIMS).